List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 232 studies with search of: "Everolimus"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC)
Condition: Hepatocellular Carcinoma
Interventions: Drug: RAD001 (everolimus);   Drug: RAD001 (everolimus)
2 Recruiting Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Drug: RAD001(Everolimus)
3 Active, not recruiting Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
Conditions: Tuberous Sclerosis;   Subependymal Giant Cell Astrocytoma
Intervention: Drug: Everolimus
4 Not yet recruiting RAD001 (Everolimus) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal
Condition: Kidney Cancer
Intervention: Drug: everolimus
5 Active, not recruiting Study of Everolimus in Patients With Recurrent Glioblastoma Multiforme
Condition: Glioblastoma Multiforme
Interventions: Drug: everolimus (RAD001);   Drug: everolimus (RAD001)
6 Recruiting Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients
Condition: Renal Transplant
Interventions: Drug: Certican (everolimus) + valganciclovir;   Drug: Valganciclovir
7 Recruiting Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium
Conditions: Bladder Cancer;   Metastatic Transitional Cell Carcinoma
Intervention: Drug: Everolimus
8 Active, not recruiting Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer
Condition: Small Cell Lung Cancer
Intervention: Drug: RAD001 (everolimus)
9 Not yet recruiting Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)
Conditions: Tuberous Sclerosis;   Angiolipoma
Intervention: Drug: everolimus (RAD001)
10 Recruiting BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)
Condition: Solid Tumors
Intervention: Drug: bevacizumab, everolimus, panitumumab
11 Recruiting RAD001 Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-Line Treatment
Condition: Stomach Neoplasm
Intervention: Drug: RAD001
12 Not yet recruiting RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: everolimus (RAD001);   Drug: erlotinib
13 Recruiting Post-Operative Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer
Condition: Head and Neck Cancer
Intervention: Other: intensity modulated radiation therapy ,RAD001 (everolimus) + Cisplatin
14 Active, not recruiting Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: RAD001;   Drug: Erlotinib
15 Recruiting Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma
Condition: Neuroendocrine Carcinoma
Interventions: Drug: Avastin;   Drug: RAD001
16 Recruiting Efficacy and Safety of RAD001 in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)
Condition: Tuberous Sclerosis
Interventions: Drug: RAD001 (Everolimus);   Drug: Placebo
17 Recruiting Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab in Adult Patients With Kidney Cancer
Conditions: Carcinoma, Renal Cell;   Adenocarcinoma, Renal Cell;   Nephroid Carcinoma;   Carcinoma, Hypernephroid
Interventions: Drug: bevacizumab, RAD001(Everolimus);   Drug: bevacizumab, interferon alfa-2a
18 Recruiting A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer
Condition: Breast Cancer
Interventions: Drug: epirubicin - cyclophosphamide / docetaxel;   Drug: epirubicin - cyclophosphamide / docetaxel + bevacizumab;   Drug: paclitaxel;   Drug: paclitaxel + everolimus (RAD001);   Drug: epirubicin - cyclophosphamide / docetaxel + trastuzumab;   Drug: epirubicin - cyclophosphamide / docetaxel + lapatinib
19 Not yet recruiting Everolimus and Low Dose CNI Compared With MMF and Full CNI Dose in Heart Transplanted Patients: One Year Follow up
Conditions: Cardiac Transplant;   Everolimus
Intervention: Drug: everolimus
20 Recruiting CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial
Conditions: Cardiac Transplantation;   Skin Cancer
Intervention: Drug: Everolimus

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services